Peri-operative immunotherapy with OK-432

Biotherapy. 1990;2(3):207-12. doi: 10.1007/BF02173521.

Abstract

Pre- and postoperative intradermal administration of OK-432 enhanced the SU-PS skin reaction in patients with gastric cancer, but failed to prevent a fall in the NK activity induced by the operation. The change in NK activity was not associated with a change in the proportion of Leu 7-positive cells, but was related to Leu 11a-positive cells. Intradermal injection of OK-432 increased the proportion of Leu 7-positive cells in the patients in whom they accounted for less than 20% of lymphocyte population. The case was the same with Leu 11a-positive cells. Intravenous injection of OK-432 tended to increase suppressor-inducer T cells (CD4+2HA+ cells), B cells and Leu 7-positive cells. Particularly, the proportions of OK-M1-positive cells and MHC class II antigen-positive cells increased in all patients. Immunotherapy with OK-432 given intravenously at a dose of 0.1 KE appeared to be safe because no side effects were essentially observed.

Publication types

  • Clinical Trial

MeSH terms

  • Combined Modality Therapy
  • Drug Administration Schedule
  • Humans
  • Immunotherapy*
  • Injections, Intravenous
  • Lymphocyte Subsets / drug effects
  • Picibanil / administration & dosage
  • Picibanil / adverse effects
  • Picibanil / therapeutic use*
  • Postoperative Care
  • Preoperative Care
  • Stomach Neoplasms / surgery
  • Stomach Neoplasms / therapy

Substances

  • Picibanil